10-K: Annual report
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Medicus Pharma Secures $4.2 Million for Innovative Skin Treatment Trials
Medicus Pharma Ltd: Promising Phase 2 Results and Market Potential Drive Buy Rating
Medicus Pharma Unveils Pricing of Financing to Advance Skin Cancer Treatment | NASDAQ:MDCX
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
Clinical Study SKNJCT-003 Shows Positive Trends as Company Advances Skin Cancer Research in UAE | NASDAQ:MDCX
Small Cap Wrap: Petro-Victory Energy, NexTech3D.ai, Medicus Pharma, Nano One Technology...
Medicus Pharma Announces Positively Trending Interim Analysis for SKNJCT-003
Medicus Pharma Reports Interim Results in Phase 2 Trial for Non-Invasive Skin Cancer Treatment, Seeks FDA Meeting After Promising 60% Clearance Rate in Basal Cell Carcinoma Study
Express News | Medicus Pharma: Plans to Submit Analysis to FDA Under Package Seeking Type C Meeting With FDA in Q2
Express News | Medicus Pharma Ltd: D-Mna Was Well Tolerated for Both Dose Levels
Wall Street Set to Open Higher Friday as Inflation Data Meets Expectations
US Stock Futures Rise as Investors Await Key Inflation Data
Extended Session Rally For Medicus (MDCX) Stock, Fueled By Regulatory Success
Market Movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma...
Medicus Pharma Expands Basal Cell Carcinoma Trial in the Middle East | NASDAQ:MDCX, TSX-V:MDCX
Medicus Pharma Shares Are Trading Higher After the Company Announced It Submitted a Phase 2 Clinical Design for SKNJCT-004 to the UAE Department of Health (DOH).
Express News | Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (Sknjct-004) to United Arab Emirates (UAE) Department of Health (Doh) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (Bcc)
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)